pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)
Shire
Shire is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome, Cytomegalovirus (CMV), Crohn's Dis
JP HQ
3,523 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 3,523
- Programs
- 9
- Drugs
- 8
- Patents
- 0
SHP615
Phase 3 · small molecule · Nervous System Diseases
SHP615 for Nervous System Diseases is a Phase 3 program (small_molecule) at Shire with 1 ClinicalTrials.gov record(s).
Internal code SHP615-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shire
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Nervous System Diseases
- Status
- completed
- Trials
- 1